Moreover, molecular monitoring is only sporadically performed in CML patients with atypical <i>BCR-ABL1</i> fusion transcripts due to lack of consensus approaches or standardization. Here, ABL1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.